AKT1 and cancer: We found common concurrent genetic alterations of the two genes, which were cooperatively associated with activation of the phosphatidylinositol 3‐kinase (PI3K)–AKT pathway, with cancer progression and mortality rates being 46.36% and 31.72% with concurrent gene alterations, versus 29.80% and 16.93% with neither gene alteration (HR 1.64, 95% CI 1.46–1.84 and 1.77, 95% CI 1.53–2.05), respectively.